Research on joint disorders
Patients with joint disorders such as OA have been found to have reduced levels of synovial lubricants that play a key role in protecting articulating cartilage. It has been suggested that where mechanical abnormalities have triggered the body’s repair process, which manifest themselves in pain and inflammation. Research has shown that liposomal aggregates that are highly compressible, soft and are highly hydrated make for efficient biolubricants. A study with topically applied, fluorescently labelled Sequessome vesicles showed that not only did the vesicles travel to the synovium, they were intact and located preferentially on the surface of the cartilage, forming a protective, lubricating layer.
Exploiting this lubricating mechanism, Flexiseq demonstrated clear efficacy in large scale Phase III 12 week trial, comparable to the oral selective, COX2 painkiller, celecoxib. These data are shown below:
Flexiseq safety profile
The excellent safety profile has been further demonstrated by the total lack of any systemic side effects being related to the product in over 90 million doses sold worldwide.
What healthcare professionals are saying about FlexiSeq
The advantages of Flexiseq have been recognised by key persons within the arthritis medical community and leading physio-therapy/sports rehabilitation:
“There are fewer and fewer safe, available, pain-relieving options for people with osteoarthritis. If this product can relieve their long-term pain without side-effects, then that’s good news for the millions of people who suffer with this debilitating condition.” Arthritis Research UK
“This is a fantastic product and one the medical team are proud and happy to have associated with the Club” – Joe Collins, former Head of Saracens Medical Team and now Head of Buffalo Sabres (ice hockey)
Medical Team Flexiseq trial data have been published in a number of journals: CURRENT Medical research and Opinion, Rheumatology, Journal of Rheumatology, and Journal of pain research.